Navidea Biopharmaceuticals, developers of Lymphoseek and novel NAV4694 announced its first quarter 2014 financial report Wednesday including word of $752,000 revenue over absolutely zero revenue for that period last year.

IBA Molecular announced today that the company will spearhead development and manufacture of Actinium Pharmaceuticals’ radioimmunotherapy for acute and refractory myeloid leukemia patients who need bone marrow transplants.

Kapil Dhingra, MBBS, previously the head of Roche Oncology, has been made a member of the board for radiopharmaceutical developers Advanced Accelerator Applications (AAA), the company announced last week.

A particular genetic allele is now deemed a protector of memory in the aging brain as demonstrated by combined genetic testing and functional MRI, according to a study published May 1 in Biological Psychology.

Dementia patients with combinations of Alzheimer’s disease (AD), Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) show significantly different distribution of the protein alpha-synuclein than they would with one diagnosis, according to a presentation during last week’s annual meeting of the American Academy of Neurology (AAN).

An investigational therapy called Neurostem-AD developed by Medipost to treat the neurodegeneration caused by Alzheimer’s disease is currently in clinical trials and is now receiving financial backing from Americord, a cord blood, tissue and placenta bank, Americord officials announced today. 

Biopharmaceutical company Lumiphore, from Berkeley, Calif., has captured a Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation to develop novel macrocyclic chelating groups in an effort to create targeted radioisotope drug delivery systems, the company announced in April.

Two researchers received awards of $130,000 each for their work in developing treatments for Alzheimer’s and the movement disorder dystonia based on their research into neurotoxins, according to an announcement from the American Academy of Neurology (AAN) during the organization’s 66th annual meeting in Philadelphia.